Search research articles
Contact Us
Filters
Showing results (321-330 of 443) with videos related to
Page
of 45
Sort By:
Bone Marrow Transplantation
|
June 19, 2025
Impact of fludarabine dose on outcome after allo-HSCT with reduced intensity conditioning for older patients with AML
Guillaume Dachy, Myriam Labopin, Gérard Socié, et al.
Bone Marrow Transplantation
|
June 13, 2020
Management of patients with acute leukemia during the COVID-19 outbreak: practical guidelines from the acute leukemia working party of the European Society for Blood and Marrow Transplantation
Eolia Brissot, Myriam Labopin, Frédéric Baron, et al.
Bone Marrow Transplantation
|
September 7, 2022
Should anti-thymocyte globulin be added in post-transplant cyclophosphamide based matched unrelated donor peripheral blood stem cell transplantation for acute myeloid leukemia? A study on behalf of the Acute Leukemia Working Party of the EBMT
Alexandros Spyridonidis, Myriam Labopin, Eolia Brissot, et al.
Blood Advances
|
January 4, 2018
Alternative donors for allogeneic hematopoietic stem cell transplantation in poor-risk AML in CR1
Jurjen Versluis, Myriam Labopin, Annalisa Ruggeri, et al.
European Journal of Haematology
|
September 20, 2014
Comparison of umbilical cord blood allogeneic stem cell transplantation vs. auto-SCT for adult acute myeloid leukemia patients in second complete remission at transplant: a retrospective study on behalf of the SFGM-TC
Patrice Chevallier, Myriam Labopin, Gerard Socie, et al.
Journal of Hematology & Oncology
|
May 29, 2023
Non-T-depleted haploidentical transplantation with post-transplant cyclophosphamide in patients with secondary versus de novo AML in first complete remission: a study from the ALWP/EBMT
Arnon Nagler, Myriam Labopin, Didier Blaise, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 22, 2024
Improvements in Posttransplant Outcomes Over Two Decades in Older Patients with Acute Myeloid Leukemia in the EBMT ALWP Study
Ali Bazarbachi, Myriam Labopin, Nour Moukalled, et al.
Bone Marrow Transplantation
|
August 20, 2024
Trends in allogeneic transplantation for favorable risk acute myeloid leukemia in first remission: a longitudinal study of >15 years from the ALWP of the EBMT
Arnon Nagler, Myriam Labopin, Urpu Salmenniemi, et al.
Bone Marrow Transplantation
|
April 13, 2024
Post-transplant cyclophosphamide, calcineurin inhibitor, and mycophenolate mofetil compared to anti-thymocyte globulin, calcineurin inhibitor, and methotrexate combinations as graft-versus-host disease prophylaxis post allogeneic stem cell transplantation from sibling and unrelated donors in patients with acute myeloid leukemia: a study on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
Arnon Nagler, Myriam Labopin, Ryszard Swoboda, et al.
Bone Marrow Transplantation
|
September 22, 2022
Comparative study of treosulfan plus Fludarabine (FT14) with busulfan plus Fludarabine (FB4) for acute myeloid leukemia in first or second complete remission: An analysis from the European Society for Blood and Marrow Transplantation (EBMT) Acute Leukemia Working Party (ALWP)
Eleni Gavriilaki, Myriam Labopin, Ioanna Sakellari, et al.
Page
of 45
Search research articles
Search
Showing results (321-330 of 443) with videos related to
Sort By:
Page
of 45
Bone Marrow Transplantation
|
June 19, 2025
Impact of fludarabine dose on outcome after allo-HSCT with reduced intensity conditioning for older patients with AML
Guillaume Dachy, Myriam Labopin, Gérard Socié, et al.
Bone Marrow Transplantation
|
June 13, 2020
Management of patients with acute leukemia during the COVID-19 outbreak: practical guidelines from the acute leukemia working party of the European Society for Blood and Marrow Transplantation
Eolia Brissot, Myriam Labopin, Frédéric Baron, et al.
Bone Marrow Transplantation
|
September 7, 2022
Should anti-thymocyte globulin be added in post-transplant cyclophosphamide based matched unrelated donor peripheral blood stem cell transplantation for acute myeloid leukemia? A study on behalf of the Acute Leukemia Working Party of the EBMT
Alexandros Spyridonidis, Myriam Labopin, Eolia Brissot, et al.
Blood Advances
|
January 4, 2018
Alternative donors for allogeneic hematopoietic stem cell transplantation in poor-risk AML in CR1
Jurjen Versluis, Myriam Labopin, Annalisa Ruggeri, et al.
European Journal of Haematology
|
September 20, 2014
Comparison of umbilical cord blood allogeneic stem cell transplantation vs. auto-SCT for adult acute myeloid leukemia patients in second complete remission at transplant: a retrospective study on behalf of the SFGM-TC
Patrice Chevallier, Myriam Labopin, Gerard Socie, et al.
Journal of Hematology & Oncology
|
May 29, 2023
Non-T-depleted haploidentical transplantation with post-transplant cyclophosphamide in patients with secondary versus de novo AML in first complete remission: a study from the ALWP/EBMT
Arnon Nagler, Myriam Labopin, Didier Blaise, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 22, 2024
Improvements in Posttransplant Outcomes Over Two Decades in Older Patients with Acute Myeloid Leukemia in the EBMT ALWP Study
Ali Bazarbachi, Myriam Labopin, Nour Moukalled, et al.
Bone Marrow Transplantation
|
August 20, 2024
Trends in allogeneic transplantation for favorable risk acute myeloid leukemia in first remission: a longitudinal study of >15 years from the ALWP of the EBMT
Arnon Nagler, Myriam Labopin, Urpu Salmenniemi, et al.
Bone Marrow Transplantation
|
April 13, 2024
Post-transplant cyclophosphamide, calcineurin inhibitor, and mycophenolate mofetil compared to anti-thymocyte globulin, calcineurin inhibitor, and methotrexate combinations as graft-versus-host disease prophylaxis post allogeneic stem cell transplantation from sibling and unrelated donors in patients with acute myeloid leukemia: a study on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
Arnon Nagler, Myriam Labopin, Ryszard Swoboda, et al.
Bone Marrow Transplantation
|
September 22, 2022
Comparative study of treosulfan plus Fludarabine (FT14) with busulfan plus Fludarabine (FB4) for acute myeloid leukemia in first or second complete remission: An analysis from the European Society for Blood and Marrow Transplantation (EBMT) Acute Leukemia Working Party (ALWP)
Eleni Gavriilaki, Myriam Labopin, Ioanna Sakellari, et al.
Page
of 45